265 related articles for article (PubMed ID: 26846787)
1. Differences in clinical findings, pathology, and outcomes between C3 glomerulonephritis and membranoproliferative glomerulonephritis.
Kawasaki Y; Kanno S; Ono A; Suzuki Y; Ohara S; Sato M; Suyama K; Hashimoto K; Hosoya M
Pediatr Nephrol; 2016 Jul; 31(7):1091-9. PubMed ID: 26846787
[TBL] [Abstract][Full Text] [Related]
2. Membranoproliferative glomerulonephritis and C3 glomerulonephritis: frequency, clinical features, and outcome in children.
Okuda Y; Ishikura K; Hamada R; Harada R; Sakai T; Hamasaki Y; Hataya H; Fukuzawa R; Ogata K; Honda M
Nephrology (Carlton); 2015 Apr; 20(4):286-92. PubMed ID: 25524631
[TBL] [Abstract][Full Text] [Related]
3. Clinico-pathologic spectrum of C3 glomerulopathy-an Indian experience.
Viswanathan GK; Nada R; Kumar A; Ramachandran R; Rayat CS; Jha V; Sakhuja V; Joshi K
Diagn Pathol; 2015 Mar; 10():6. PubMed ID: 25889427
[TBL] [Abstract][Full Text] [Related]
4. Morphological and etiological analyses of C3 and non-C3 glomerulonephritis in primary membranoproliferative glomerulonephritis using periodic acid-methenamine silver stain electron microscopy: a retrospective multicentered study.
Honma S; Sato N; Sakaguchi R; Hashiguchi A; Uesugi N; Nakamura Y; Sasano H; Joh K
Med Mol Morphol; 2024 Mar; 57(1):23-34. PubMed ID: 37823929
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics and outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulopathy in Japanese children.
Ueda C; Horinouchi T; Inoki Y; Ichikawa Y; Tanaka Y; Kitakado H; Kondo A; Sakakibara N; Nagano C; Yamamura T; Fujimura J; Kamiyoshi N; Ishimori S; Ninchoji T; Kaito H; Shima Y; Iijima K; Nozu K; Yoshikawa N
Pediatr Nephrol; 2024 Apr; ():. PubMed ID: 38662234
[TBL] [Abstract][Full Text] [Related]
6. Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy.
Kersnik Levart T; Ferluga D; Vizjak A; Mraz J; Kojc N
Diagn Pathol; 2016 Oct; 11(1):94. PubMed ID: 27717365
[TBL] [Abstract][Full Text] [Related]
7. Demographic, clinical characteristics and treatment outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulonephritis in Japan: A retrospective analysis of data from the Japan Renal Biopsy Registry.
Nakagawa N; Mizuno M; Kato S; Maruyama S; Sato H; Nakaya I; Sugiyama H; Fujimoto S; Miura K; Matsumura C; Gotoh Y; Suzuki H; Kuroki A; Yoshino A; Nakatani S; Hiromura K; Yamamoto R; Yokoyama H; Narita I; Isaka Y
PLoS One; 2021; 16(9):e0257397. PubMed ID: 34520493
[TBL] [Abstract][Full Text] [Related]
8. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
Front Immunol; 2018; 9():2329. PubMed ID: 30487789
[TBL] [Abstract][Full Text] [Related]
9. C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial.
Ruggenenti P; Daina E; Gennarini A; Carrara C; Gamba S; Noris M; Rubis N; Peraro F; Gaspari F; Pasini A; Rigotti A; Lerchner RM; Santoro D; Pisani A; Pasi A; Remuzzi G;
Am J Kidney Dis; 2019 Aug; 74(2):224-238. PubMed ID: 30929851
[TBL] [Abstract][Full Text] [Related]
10. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.
Servais A; Frémeaux-Bacchi V; Lequintrec M; Salomon R; Blouin J; Knebelmann B; Grünfeld JP; Lesavre P; Noël LH; Fakhouri F
J Med Genet; 2007 Mar; 44(3):193-9. PubMed ID: 17018561
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of membranoproliferative glomerulonephritis based on a new classification at a single center.
Nakano M; Karasawa K; Moriyama T; Uchida K; Nitta K
Clin Exp Nephrol; 2019 Jun; 23(6):852-858. PubMed ID: 30854618
[TBL] [Abstract][Full Text] [Related]
12. C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy.
Bomback AS; Santoriello D; Avasare RS; Regunathan-Shenk R; Canetta PA; Ahn W; Radhakrishnan J; Marasa M; Rosenstiel PE; Herlitz LC; Markowitz GS; D'Agati VD; Appel GB
Kidney Int; 2018 Apr; 93(4):977-985. PubMed ID: 29310824
[TBL] [Abstract][Full Text] [Related]
13. Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents.
Holle J; Berenberg-Goßler L; Wu K; Beringer O; Kropp F; Müller D; Thumfart J
Pediatr Nephrol; 2018 Dec; 33(12):2289-2298. PubMed ID: 30238151
[TBL] [Abstract][Full Text] [Related]
14. Therapy and outcomes of C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis.
Khandelwal P; Bhardwaj S; Singh G; Sinha A; Hari P; Bagga A
Pediatr Nephrol; 2021 Mar; 36(3):591-600. PubMed ID: 32886193
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological features of membranoproliferative glomerulonephritis under a new classification.
Nargund P; Kambham N; Mehta K; Lafayette RA
Clin Nephrol; 2015 Dec; 84(6):323-30. PubMed ID: 26445002
[TBL] [Abstract][Full Text] [Related]
16. C3 glomerulonephritis with a severe crescentic phenotype.
Ravindran A; Fervenza FC; Smith RJH; Sethi S
Pediatr Nephrol; 2017 Sep; 32(9):1625-1633. PubMed ID: 28593446
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic and Prognostic Comparison of Immune-Complex-Mediated Membranoproliferative Glomerulonephritis and C3 Glomerulopathy.
Kovala M; Seppälä M; Räisänen-Sokolowski A; Meri S; Honkanen E; Kaartinen K
Cells; 2023 Feb; 12(5):. PubMed ID: 36899849
[TBL] [Abstract][Full Text] [Related]
18. Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies.
Rudnicki M
Biomed Res Int; 2017; 2017():2180508. PubMed ID: 28573137
[TBL] [Abstract][Full Text] [Related]
19. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN.
Iatropoulos P; Daina E; Curreri M; Piras R; Valoti E; Mele C; Bresin E; Gamba S; Alberti M; Breno M; Perna A; Bettoni S; Sabadini E; Murer L; Vivarelli M; Noris M; Remuzzi G; ;
J Am Soc Nephrol; 2018 Jan; 29(1):283-294. PubMed ID: 29030465
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors for poor outcome in pediatric C3 glomerulonephritis.
Hosoya M; Kawasaki Y; Maeda R; Sato M; Suyama K; Hashimoto K; Hosoya M
Fukushima J Med Sci; 2018 Dec; 64(3):142-150. PubMed ID: 30369521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
